Silence Therapeutics PLC Director/PDMR Shareholding (9003U)
18 July 2018 - 12:00AM
UK Regulatory
TIDMSLN
RNS Number : 9003U
Silence Therapeutics PLC
17 July 2018
Grant of Restricted Stock Units
17 July 2018
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a
leader in the discovery, delivery and development of novel RNA
therapeutics for the treatment of serious diseases with unmet
medical need, announces that it has today granted nominal cost
restricted stock units ('RSUs') to David Horn Solomon, the
Company's Chief Executive Officer, under the Silence Therapeutics
plc 2018 Long Term Incentive Plan. Details of the grant are
summarised below.
Award of Restricted Stock Units:
Director Position RSUs Awarded Total RSUs Held
David Horn Solomon CEO 401,338 401,338
---------- ------------- ----------------
These nominal cost RSUs will vest in full on 16 July 2021. The
RSUs are subject to achievement of the performance condition that
the Company's share price must be maintained above 157p for a
period of 30 continuous days prior to vesting. The RSUs are
exercisable over the period of 7 years from the date of vesting.
Claw-back and malus provisions apply. There is a one-year holding
period post exercise. Each RSU entitles the holder to subscribe for
an Ordinary Share at a subscription price of 5 pence per Ordinary
Share equating to the nominal value.
The notifications set out below are provided in accordance with
the requirements of the EU Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name David Horn Solomon
------------------------------- -----------------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------------- -----------------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- -----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------
a) Name Silence Therapeutics plc
------------------------------- -----------------------------------------------
b) LEI 213800SSURRJBX85SQ91
------------------------------- -----------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
--------------------------------------------------------------------------------
a) Description of the financial Ordinary shares of 5 pence each
instrument, type of instrument
ISIN for Silence Therapeutics plc Ordinary
Identification code Shares GB00B9GTXM62
------------------------------- -----------------------------------------------
b) Nature of the transaction Grant of restricted stock units under the
Silence Therapeutics plc 2018 Long Term
Incentive Plan
------------------------------- -----------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
5 pence per share (subscription price) 401,338
------------------------------- -----------------------------------------------
d) Aggregated information
- Aggregated volume N/A
- Price
------------------------------- -----------------------------------------------
e) Date of the transaction 17 July 2018
------------------------------- -----------------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------- -----------------------------------------------
Enquiries:
Silence Therapeutics plc Tel: +44 (0) 20 3457
Annalisa Jenkins, Executive Chair 6900
David Horn Solomon, Chief Executive Officer
David Ellam, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Broker) Tel: +44 (0) 20 7418
James Steel/ Oliver Jackson 8900
Media & IR Enquiries Tel: +44 (0) 20 3714
Optimum Strategic Communications 1788
Mary Clark/ Eva Haas/ Hollie Vile
silence@optimumcomms.com
IR Enquiries - US Tel: +1 (212) 213
Burns McClellan 0006
John Grimaldi
Silence.Therapeutics@burnsmc.com
About Silence Therapeutics plc
Silence Therapeutics is developing a new modality of genetic
medicines by harnessing the body's natural mechanism of RNA
interference, or RNAi, within its cells. Its proprietary technology
can selectively inhibit any gene in the genome and be engineered to
specifically silence the production of disease-associated proteins.
Using enabling delivery systems, Silence has achieved an additional
level of specificity by delivering therapeutic RNA molecules
exclusively to target cells. Silence's proprietary technology
platform provides an effective, safe and highly potent modular
approach well suited to tackling life-threatening diseases. Silence
aims on being a clinical stage company in 2019, while progressing a
pipeline of earlier stage candidates against important gene targets
directed at areas of high unmet medical need. In parallel, Silence
continues to evolve its patent portfolio as new discoveries emerge
from its innovative efforts to develop the next generation of RNAi
medicines.
Silence has out-licensed technology to Quark Pharmaceuticals for
use in Delayed Graft Function and Acute Kidney Injury. Both
programmes are now in phase III. For more information, please
visit: http://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHBGGDRUXBBGIR
(END) Dow Jones Newswires
July 17, 2018 10:00 ET (14:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024